Vertex Pharmaceuticals

Vertex gains reimbursement agreement in Italy for cystic fibrosis drug Orkambi

Friday, July 14, 2017

Vertex Pharmaceuticals announced that the Italian Medicines Agency (Agenzia Italiana del Farmaco, or AIFA) has agreed to reimburse Orkambi (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF) in people ages 12 and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The agreement is published online in the Italian Official Gazette.

[Read More]

X-Chem, Vertex enter genetic disease collaboration

Wednesday, May 17, 2017

X-Chem, a privately held biotechnology company applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, announced a collaboration with Vertex Pharmaceuticals. X-Chem will apply its proprietary DEXTM libraries, which contain more than 120 billion small molecules, toward the discovery of new drug leads against targets involved in multiple specialty diseases. Vertex will have the option to license lead-like hits discovered under the collaboration, and will be responsible for further development and commercialization of the resulting programs.

[Read More]

Bristol-Myers Squibb appoints three new independent directors

Tuesday, February 21, 2017

Bristol-Myers Squibb has appointed Robert J. Bertolini, Matthew W. Emmens and Theodore R. Samuels to its board of directors, effective immediately. In connection with these appointments, the board will temporarily expand to 14 directors until the 2017 Annual Meeting, to be held on May 2, 2017. Only 11 directors will stand for election at the meeting. Bristol-Myers Squibb also announced that it has entered into an accelerated share repurchase (ASR) program to repurchase, in aggregate, $2 billion of Bristol-Myers Squibb’s common stock.

[Read More]

Concert’s CTP-656 receives FDA Orphan designation for cystic fibrosis

Monday, January 23, 2017

Concert Pharmaceuticals has announced that the FDA has granted Orphan Drug designation for CTP-656, Concert’s next generation CFTR potentiator being developed for the treatment of cystic fibrosis. In December 2016, Concert initiated a phase II trial in the U.S. evaluating CTP-656 in cystic fibrosis patients with gating mutations. Topline results from the phase II trial are expected by year-end 2017.

[Read More]

AMRI hires Jimmy Wang as chief information officer

Wednesday, February 11, 2015

Albany Molecular Research (AMRI), a global contract research and manufacturing organization, has hired Jimmy Wang, Ph.D., to fill the newly created position of chief information officer, effective immediately. He replaces Carl Neumann, senior director, information technology, who retires this month.

[Read More]

Vertex cuts workforce 15%

Wednesday, October 30, 2013

Global biotech Vertex Pharmaceuticals will focus its investment on future opportunities in cystic fibrosis and other high-potential R&D programs and is reducing its workforce related to the support of INCIVEK, because of the continued and rapid decline in the number of people being treated with INCIVEK as other new medicines for hepatitis C near approval.

[Read More]